YU8302A - Upotreba cgrp-antagonista i cgrp-release-inhibitora za suzbijanje menopauznih toplotnih valunga - Google Patents

Upotreba cgrp-antagonista i cgrp-release-inhibitora za suzbijanje menopauznih toplotnih valunga

Info

Publication number
YU8302A
YU8302A YU8302A YUP8302A YU8302A YU 8302 A YU8302 A YU 8302A YU 8302 A YU8302 A YU 8302A YU P8302 A YUP8302 A YU P8302A YU 8302 A YU8302 A YU 8302A
Authority
YU
Yugoslavia
Prior art keywords
cgrp
release inhibitors
antagonists
hot flashes
menopausal hot
Prior art date
Application number
YU8302A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Henri Doods
Klaus Rudolf
Wolfgang Eberlein
Wolfhard Engel
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Publication of YU8302A publication Critical patent/YU8302A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
YU8302A 1999-08-10 2000-08-05 Upotreba cgrp-antagonista i cgrp-release-inhibitora za suzbijanje menopauznih toplotnih valunga YU8302A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19937304A DE19937304C2 (de) 1999-08-10 1999-08-10 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen

Publications (1)

Publication Number Publication Date
YU8302A true YU8302A (sh) 2004-12-31

Family

ID=7917551

Family Applications (1)

Application Number Title Priority Date Filing Date
YU8302A YU8302A (sh) 1999-08-10 2000-08-05 Upotreba cgrp-antagonista i cgrp-release-inhibitora za suzbijanje menopauznih toplotnih valunga

Country Status (32)

Country Link
EP (1) EP1207884B1 (https=)
JP (1) JP2003506403A (https=)
KR (1) KR100713573B1 (https=)
CN (1) CN1166361C (https=)
AR (1) AR025078A1 (https=)
AT (1) ATE281168T1 (https=)
AU (1) AU777709B2 (https=)
BG (1) BG65366B1 (https=)
BR (1) BR0013009A (https=)
CA (1) CA2378428C (https=)
CZ (1) CZ300513B6 (https=)
DE (2) DE19937304C2 (https=)
EA (1) EA007531B1 (https=)
EE (1) EE04928B1 (https=)
ES (1) ES2231243T3 (https=)
HK (1) HK1046854B (https=)
HR (1) HRP20020117A2 (https=)
HU (1) HUP0202397A3 (https=)
IL (1) IL148057A (https=)
MX (1) MXPA02001373A (https=)
MY (1) MY129668A (https=)
NO (1) NO20020605D0 (https=)
NZ (1) NZ517367A (https=)
PL (1) PL198483B1 (https=)
PT (1) PT1207884E (https=)
SK (1) SK285587B6 (https=)
TR (1) TR200200359T2 (https=)
TW (1) TWI285550B (https=)
UA (1) UA73137C2 (https=)
WO (1) WO2001010425A2 (https=)
YU (1) YU8302A (https=)
ZA (1) ZA200200997B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
WO2003050109A1 (en) * 2001-12-12 2003-06-19 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10227294A1 (de) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2005004869A1 (en) * 2003-07-07 2005-01-20 Boehringer Ingelheim International Gmbh Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
CN100418948C (zh) * 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2132855T3 (es) * 1995-09-07 1999-08-16 Oreal Extracto de iridaceas y composiciones que lo contienen.
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
DE59711622D1 (de) * 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19911039A1 (de) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CZ2002497A3 (cs) 2002-06-12
JP2003506403A (ja) 2003-02-18
EE04928B1 (et) 2007-12-17
AU6992800A (en) 2001-03-05
HK1046854A1 (en) 2003-01-30
TR200200359T2 (tr) 2002-05-21
WO2001010425A2 (de) 2001-02-15
SK285587B6 (sk) 2007-04-05
ES2231243T3 (es) 2005-05-16
EP1207884B1 (de) 2004-11-03
KR100713573B1 (ko) 2007-05-02
UA73137C2 (en) 2005-06-15
DE50008527D1 (de) 2004-12-09
CZ300513B6 (cs) 2009-06-03
AR025078A1 (es) 2002-11-06
EA200200207A1 (ru) 2002-08-29
HUP0202397A2 (en) 2002-10-28
ZA200200997B (en) 2002-10-30
CN1166361C (zh) 2004-09-15
MXPA02001373A (es) 2002-07-30
IL148057A0 (en) 2002-09-12
HK1046854B (zh) 2005-02-25
TWI285550B (en) 2007-08-21
NO20020605L (no) 2002-02-07
NO20020605D0 (no) 2002-02-07
DE19937304A1 (de) 2001-03-15
MY129668A (en) 2007-04-30
SK1972002A3 (en) 2002-06-04
PT1207884E (pt) 2004-12-31
CA2378428C (en) 2009-10-20
PL364049A1 (en) 2004-12-13
CA2378428A1 (en) 2001-02-15
AU777709B2 (en) 2004-10-28
BR0013009A (pt) 2002-04-30
PL198483B1 (pl) 2008-06-30
EP1207884A2 (de) 2002-05-29
KR20020016947A (ko) 2002-03-06
EE200200061A (et) 2003-04-15
BG65366B1 (bg) 2008-04-30
CN1370069A (zh) 2002-09-18
EA007531B1 (ru) 2006-10-27
HRP20020117A2 (en) 2003-10-31
WO2001010425A3 (de) 2002-02-07
DE19937304C2 (de) 2003-08-21
IL148057A (en) 2008-04-13
BG106391A (bg) 2002-09-30
ATE281168T1 (de) 2004-11-15
NZ517367A (en) 2004-09-24
HUP0202397A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
YU8302A (sh) Upotreba cgrp-antagonista i cgrp-release-inhibitora za suzbijanje menopauznih toplotnih valunga
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
PT1076644E (pt) Aminotetralinas substituidas emn como ligandos para o receptor de neuropeptideoy y5 util no tratamento da obesidade e de outras perturbacoes
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
MY129150A (en) Novel sulfamides
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
DK1207756T3 (da) Anvendelse af spinosad eller en formulering, der omfatter spinosad
ATE300541T1 (de) Pyrazolopyridinderivate
BR0111678A (pt) Composições medicinais contendo derivados de propenona
PT1150686E (pt) Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina
WO2005065639A3 (en) Novel pharmaceutical compositions
YU39201A (sh) Upotreba 1-arilpirazola za pripremanje oralnog sredstva za suzbijanje parazita
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
TR200100637T2 (tr) Yeni doğal ürün türevleri
YU25001A (sh) Optički aktivan derivat piridil-4h-1,2,4-oksadiazina i njegova upotreba u proizvodnji lekova za tretiranje vaskularnih bolesti
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
NO20014961L (no) Integrin-reseptor-ligander
ATE286395T1 (de) Antithrombotische mittel
SE9803107D0 (sv) Novel Compunds
HRP20050466A2 (en) Pharmaceutical composition comprising a ltb4 antagonists and a cox-2 inhibitor or a combined cox 1/2 inhibitor
DK1257538T3 (da) 9-alkylamino-1-nitroacridin-derivater